Welcome to the Amyloidosis Center at Heidelberg University Hospital
Amyloidoses are usually illnesses that affect the whole body. It is therefore necessary to view them from multiple perspectives.
A group of experts from various fields has come together at the Amyloidosis Center at Heidelberg University Hospital to collaboratively diagnose and treat the rare medical condition amyloidosis. We use our extensive knowledge on an interdisciplinary basis to provide the best possible treatment for our patients.
Medical specialists from the following departments work collaboratively at the Amyloidosis Center in Heidelberg:
- Cardiac surgery
- Human genetics
- Nuclear medicine
The success of this close cooperation is reflected by the continuously increasing number of patients from all parts of Germany treated at Heidelberg University Hospital, which currently treats more than 600 patients with systemic amyloidosis, the largest group of such patients in the country. Treatment is provided in different departments of the medical center, depending on the treatment focus.
After a specific diagnosis has been established regarding the type of amyloidosis, the medical specialists at our Amyloidosis Center will recommend an individual, interdisciplinary treatment strategy that matches the type and extent of the disorder. The strategy will be aimed at the cause of the disorder and will attempt to prevent additional amyloid being deposited. The therapy must start as early as possible, as amyloid that has already been deposited cannot be removed from the tissues.
Our treatment plans range from a targeted treatment of the underlying, chronic inflammation associated with AA amyloidosis using medications, to high-dose chemotherapy followed by the transplantation of blood stem cells from bone marrow in the case of light chain amyloidosis, all the way to a liver transplant for familial amyloidosis.
We provide supportive treatment for individual organ problems that occur in all amyloidosis types.
Currently, the safety and efficacy of various medical therapies are being investigated in several clinical studies.
If you have any questions, please feel free to contact us.
Dr. Stefan Schönland
Spokesman for the Amyloidosis Center at Heidelberg University Hospital